Inclusion Criteria:

          1. Patients with PD-L1 positive, recurrent or metastatic malignant tumors , including but
             not limited to pancreatic cancer, renal cancer, colorectal cancer, lymphoma, breast
             cancer and lung cancer;

          2. measurable tumors by RECIST1.1 standard;

          3. patients are 18 to 70 years old;

          4. life expectancy > 3months;

          5. KPS ≥70;

          6. satisfactory major organ functions: adequate heart function with LVEF≥50%; no obvious
             abnormities in ECG; pulse oximetry ≥ 90%; cockcroft-gault creatinine clearance≥40
             ml/min; alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3ULN;
             Bilirubin ≤2.0 mg/dl ;

          7. Blood: Hgb ≥ 80 g/L, ANC ≥ 1×10^9/L, PLT ≥ 50×10^9/L;

          8. women of reproductive potential must have a negative pregnancy test. Male and female
             of reproductive potential must agree to use birth control during the study and one
             year post study.

        Exclusion Criteria:

          1. patients with a prior history of autoimmune disease or other diseases who need
             long-term use of systemic hormone drug or immunosuppressive therapy

          2. active infection.

          3. HIV positive.

          4. active hepatitis B virus infection or hepatitis C virus infection.

          5. currently enrolled in other study.

          6. patients, in the opinion of investigators, may not be eligible or are not able to
             comply with the study.

          7. patients with allergic disease, or are allergic to T cell products or other biological
             agents used in the study.

          8. patients whose tumors have metastasized to bone, or have clinical signs of bone
             metastasis, such as bone and joint pain.

          9. patients with brain metastasis, or have clinical signs of brain metastasis, such as
             loss of self-consciousness.